CLINICAL_TRIALS
trial_result
· 2024-05-09
Clinical Trial Update: A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis. [Phase 2]
Summary
Phase 2 trial evaluating CMK389 for moderate to severe Atopic Dermatitis has completed and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2024-05-09